



For more information, visit: <http://www.prisma-statement.org/>  
**Supplemental Figure S1. PRISMA flow diagram [36]**

**Supplemental Table S1.** Newcastle-Ottawa rating scale results for the included studies

Study ID	Representativeness	Selection of non-exposed	Ascertainment of exposure	Outcome not present at start	Comparability on major factor	Comparability on other factors	Assessment of outcome	Long enough follow-up	Adequacy of follow-up	Total score
Torregrosa 2015 [26]	1	1	1	1	1	0	1	1	1	8
Yong-Jun Liu 2015 [40]	1	1	1	1	1	0	1	1	1	8
Yingying 2019 [27]	1	1	1	1	1	0	1	1	1	8
Ales Jerin 2020 [28]	1	1	1	1	1	0	1	1	1	8

**Supplemental Table S2.** Comorbidities of included patients

Study ID	Hypertension		Dyslipidemia		Congestive heart failure		Peripheral artery disease		Cerebrovascular disease		Diabetes mellitus	
	<i>AKI</i>	<i>Non-AKI</i>	<i>AKI</i>	<i>Non-AKI</i>	<i>AKI</i>	<i>Non-AKI</i>	<i>AKI</i>	<i>Non-AKI</i>	<i>AKI</i>	<i>Non-AKI</i>	<i>AKI</i>	<i>Non-AKI</i>
Torregrosa et al., 2014 [26]	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR
Yong-Jun Liu et al., 2015 [40]	4/19 (21.1%)	2/16 (12.5%)	NR	NR	NR	NR	NR	NR	NR	NR	3/19 (15.7%)	1/16 (6.2%)
Yingying Qian et al., 2019 [27]	13/33 (39.4%)	20/58 (34.5%)	1/33 (3.0%)	5/58 (8.6%)	7/33 (21.2%)	6/58 (10.3%)	NR	NR	0/33 (0%)	4/58 (6.9%)	6/33 (18.1%)	8/58 (13.8%)

Ales Jerin et al., 2020 [28]	10/52 (19.2%)	6/26 (23.1%)	NR	NR	NR	NR	NR	NR	NR	NR	16/52 (30.7%)	9/26 (34.6%)
<b>Total</b>	27/104 (25.9%)	28/100 (28%)	1/33 (3%)	5/58 (8.6%)	7/33 (21.2%)	6/58 (10.3%)	NR	NR	0/33 (0%)	4/58 (6.9%)	25/104 (24%)	18/100 (18%)

*ID: identification; AKI: acute kidney injury; NR: not reported*